Charles River Laboratories International, Inc. (CRL) Income Statement Analysis

See more : Arlo Technologies, Inc. (ARLO) Income Statement Analysis – Financial Results

Complete financial analysis of Charles River Laboratories International, Inc. (CRL) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Charles River Laboratories International, Inc., a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.

You may be interested

Shenzhen Sunlord Electronics Co.,Ltd. (002138.SZ) Income Statement Analysis – Financial Results
Zwahlen & Mayr SA (0QLY.L) Income Statement Analysis – Financial Results
S R G Securities Finance Limited (SRGSFL.BO) Income Statement Analysis – Financial Results
Farfetch Limited (FTCHF) Income Statement Analysis – Financial Results
The Home Depot, Inc. (HDI.DE) Income Statement Analysis – Financial Results

Charles River Laboratories International, Inc. (CRL)

Industry: Medical - Diagnostics & Research

Sector: Healthcare

Website: https://www.criver.com

About Charles River Laboratories International, Inc.

Charles River Laboratories International, Inc., a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodent research model strains and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines. The company also provides contract vivarium operation services to biopharmaceutical clients. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.

Metric	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003	2002	2001	2000	1999	1998
Revenue	4.13B	3.98B	3.54B	2.92B	2.62B	2.27B	1.86B	1.68B	1.36B	1.30B	1.17B	1.13B	1.14B	1.13B	1.20B	1.34B	1.23B	1.06B	1.12B	766.92M	613.72M	554.63M	465.63M	306.59M	219.28M	193.30M
Cost of Revenue	2.63B	2.51B	2.21B	1.85B	1.66B	1.43B	1.16B	1.03B	832.21M	825.00M	770.63M	737.45M	740.41M	748.66M	773.18M	832.78M	752.44M	651.78M	693.49M	468.35M	380.06M	345.65M	298.38M	171.45M	120.91M	122.55M
Gross Profit	1.50B	1.46B	1.33B	1.07B	958.31M	840.07M	702.31M	646.67M	531.09M	472.66M	394.90M	392.08M	402.24M	384.76M	429.37M	510.71M	478.19M	406.61M	428.74M	298.57M	233.67M	208.98M	167.25M	135.14M	98.37M	70.75M
Gross Profit Ratio	36.39%	36.79%	37.70%	36.72%	36.56%	37.07%	37.81%	38.46%	38.96%	36.42%	33.88%	34.71%	35.20%	33.95%	35.70%	38.01%	38.86%	38.42%	38.20%	38.93%	38.07%	37.68%	35.92%	44.08%	44.86%	36.60%
Research & Development	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
General & Administrative	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Selling & Marketing	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
SG&A	747.86M	665.10M	619.92M	528.94M	517.62M	443.85M	373.45M	367.55M	300.41M	269.03M	225.70M	208.25M	206.14M	262.49M	234.00M	230.16M	217.49M	180.80M	189.54M	121.45M	90.24M	83.30M	68.32M	51.20M	39.77M	34.14M
Other Expenses	0.00	146.58M	124.86M	111.88M	89.54M	13.26M	38.54M	11.90M	3.01M	10.72M	7.17M	-3.27M	21.80M	24.41M	28.45M	30.31M	33.51M	37.64M	58.17M	16.80M	4.88M	3.41M	8.65M	18.87M	15.64M	1.29M
Operating Expenses	885.30M	811.68M	744.78M	640.81M	607.16M	508.68M	414.82M	409.25M	324.64M	294.99M	243.50M	226.32M	227.94M	286.89M	262.44M	260.47M	251.00M	218.43M	247.72M	138.24M	95.11M	86.72M	76.97M	70.07M	55.41M	35.43M
Cost & Expenses	3.51B	3.33B	2.95B	2.49B	2.27B	1.93B	1.57B	1.44B	1.16B	1.12B	1.01B	963.77M	968.34M	1.04B	1.04B	1.09B	1.00B	870.21M	941.21M	606.59M	475.17M	432.36M	375.35M	241.52M	176.31M	157.98M
Interest Income	5.20M	780.00K	652.00K	834.00K	1.52M	812.00K	690.00K	1.31M	1.04M	1.15M	730.00K	589.00K	1.35M	1.19M	1.78M	8.69M	9.68M	6.84M	3.93M	3.29M	0.00	2.12M	1.49M	0.00	0.00	0.00
Interest Expense	136.71M	59.29M	73.91M	86.43M	60.88M	63.77M	29.78M	27.71M	15.07M	11.95M	20.97M	33.34M	41.23M	34.09M	21.68M	14.01M	14.83M	193.24M	22.62M	8.65M	6.56M	27.34M	27.28M	67.35M	8.28M	0.00
Depreciation & Amortization	314.12M	303.87M	265.54M	234.92M	198.10M	161.78M	131.16M	126.66M	24.23M	25.96M	17.81M	18.07M	21.80M	24.41M	28.45M	30.31M	88.92M	85.13M	104.64M	48.18M	31.12M	25.73M	28.58M	18.87M	15.64M	10.90M
EBITDA	1.03B	1.04B	854.29M	759.15M	581.73M	507.23M	457.89M	377.29M	305.38M	285.99M	255.54M	244.36M	260.48M	-205.15M	263.20M	-355.82M	321.81M	273.30M	274.81M	210.64M	138.55M	147.99M	90.28M	83.93M	58.61M	46.22M
EBITDA Ratio	24.99%	24.80%	23.17%	26.28%	21.48%	18.11%	19.82%	17.39%	16.92%	15.69%	14.52%	16.28%	17.16%	10.79%	16.07%	73.43%	25.80%	25.73%	25.47%	27.09%	27.52%	26.46%	25.42%	27.02%	25.82%	23.94%
Operating Income	617.26M	650.98M	589.86M	432.73M	351.15M	331.38M	287.50M	237.42M	206.45M	177.67M	151.40M	165.77M	174.31M	-298.51M	166.93M	-449.76M	227.19M	188.17M	181.02M	160.32M	138.55M	122.27M	90.28M	65.06M	42.96M	35.33M
Operating Income Ratio	14.95%	16.37%	16.66%	14.80%	13.40%	14.62%	15.48%	14.12%	15.14%	13.69%	12.99%	14.68%	15.25%	-26.34%	13.88%	-33.48%	18.46%	17.78%	16.13%	20.90%	22.58%	22.04%	19.39%	21.22%	19.59%	18.27%
Total Other Income/Expenses	-35.98M	-27.99M	-109.15M	14.39M	-47.07M	-49.70M	8.67M	-14.50M	-11.02M	-75.00K	-13.07M	-36.02M	-41.64M	-35.57M	-17.82M	-10.14M	-9.77M	-11.61M	-17.13M	-9.86M	-5.92M	-37.75M	-27.78M	-39.35M	-10.28M	507.00K
Income Before Tax	581.28M	622.99M	480.71M	447.11M	304.08M	281.68M	296.96M	222.92M	195.43M	177.60M	138.33M	129.75M	132.66M	-334.08M	149.11M	-461.01M	217.42M	176.56M	160.41M	152.53M	132.63M	114.40M	69.48M	25.71M	32.69M	35.83M
Income Before Tax Ratio	14.08%	15.67%	13.58%	15.29%	11.60%	12.43%	15.99%	13.26%	14.33%	13.69%	11.87%	11.49%	11.61%	-29.48%	12.40%	-34.31%	17.67%	16.68%	14.29%	19.89%	21.61%	20.63%	14.92%	8.39%	14.91%	18.54%
Income Tax Expense	100.91M	130.38M	81.87M	81.81M	50.02M	54.46M	171.37M	66.84M	43.39M	47.67M	32.91M	27.63M	17.14M	23.00K	39.73M	61.94M	59.40M	49.74M	16.58M	61.16M	51.06M	43.57M	27.10M	7.84M	15.56M	14.12M
Net Income	474.62M	486.23M	390.98M	364.30M	252.02M	226.37M	123.36M	154.77M	149.31M	126.70M	102.83M	97.30M	109.57M	-336.67M	114.44M	-521.84M	154.41M	-55.78M	142.00M	89.79M	80.15M	50.13M	35.41M	-11.22M	17.12M	23.38M
Net Income Ratio	11.49%	12.23%	11.04%	12.46%	9.61%	9.99%	6.64%	9.20%	10.95%	9.76%	8.82%	8.61%	9.59%	-29.70%	9.52%	-38.84%	12.55%	-5.27%	12.65%	11.71%	13.06%	9.04%	7.60%	-3.66%	7.81%	12.09%
EPS	9.27	9.57	7.77	7.35	5.17	4.72	2.60	3.29	3.21	2.72	2.15	2.03	2.16	-5.38	1.75	-7.76	2.31	-0.81	2.04	1.81	1.76	1.12	0.86	-0.40	0.86	2.27
EPS Diluted	9.22	9.48	7.60	7.20	5.07	4.62	2.54	3.23	3.13	2.66	2.12	2.01	2.14	-5.38	1.74	-7.76	2.25	-0.80	1.96	1.67	1.64	1.06	0.80	-0.35	0.86	2.27
Weighted Avg Shares Out	51.23M	50.81M	50.29M	49.55M	48.73M	47.95M	47.48M	47.01M	46.50M	46.63M	47.74M	47.91M	50.82M	62.56M	65.37M	67.27M	66.96M	68.87M	69.61M	49.60M	45.54M	44.76M	41.17M	28.06M	19.82M	10.29M
Weighted Avg Shares Out (Dil)	51.45M	51.30M	51.43M	50.61M	49.69M	49.02M	48.56M	47.96M	47.63M	47.56M	48.49M	48.41M	51.32M	62.56M	65.64M	67.27M	68.74M	69.73M	72.45M	56.05M	48.87M	47.29M	44.26M	32.07M	19.82M	10.29M

Charles River (CRL) Could be an Apt Pick Right Now: Here's Why

July 5, 2024zacks.com

Investors are optimistic about Charles River (CRL) due to its business performance and strategic buyouts.

Charles River's (CRL) RMS Growth Aids Amid FX Headwind

June 27, 2024zacks.com

Charles River (CRL) broadens the scope of its products and services across the drug discovery and early-stage development continuum through focused acquisitions.

Charles River (CRL) Inks CDMO Deal With Gates Institutes

June 26, 2024zacks.com

Charles River (CRL) signs a lentiviral vector contract development and manufacturing organization agreement with Gates Institute to help develop chimeric antigen receptor (CAR) T-cell therapies.

Charles River Laboratories Announces Strategic Lentiviral Vector Manufacturing Collaboration with Gates Institute at University of Colorado Anschutz Medical Campus

June 25, 2024businesswire.com

ROCKVILLE, Md.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) and the Gates Institute at the University of Colorado Anschutz Medical Campus today announced a lentiviral vector contract development and manufacturing organization (CDMO) agreement. Gates Institute will leverage Charles River's premier...

Charles River (CRL) Advances in T-Cell Therapy With New Alliance

June 18, 2024zacks.com

Charles River (CRL) and Captain T Cell announced an agreement on plasmid DNA and retrovirus vector production program for the treatment of patients having solid tumor.

CRL INVESTIGATION ALERT: Johnson Fistel LLP Investigates Charles River Laboratories' Directors and Officers for Breach of Fiduciary Duties

June 17, 2024accesswire.com

SAN DIEGO, CA / ACCESSWIRE / June 17, 2024 / Johnson Fistel, LLP (www.johnsonfistel.com), a shareholder rights law firm, announces its continuing investigation of whether certain directors and officers of Charles River Laboratories International, Inc. (NYSE:CRL) breached their fiduciary duties...

Charles River and Captain T Cell Announce Plasmid DNA and Viral Vector Manufacturing Alliance for Gene-Modified Cell Therapy

June 17, 2024businesswire.com

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) and Captain T Cell, a spinoff from the renowned Max Delbrück Center Berlin, Germany, today announced a plasmid DNA and retrovirus vector production program agreement. As part of Charles River's Cell...

Outlook Therapeutics: Worth A Good Strong Look After CRL

June 13, 2024seekingalpha.com

Outlook Therapeutics received a Complete Response Letter from the FDA in August 2023, causing a 74% drop in share price. Following a Type A meeting with the FDA in November 2023, Outlook agreed to conduct an additional clinical trial for...

CRL INVESTIGATION ALERT: Johnson Fistel LLP Investigates Charles River Laboratories' Directors and Officers for Breach of Fiduciary Duties

June 12, 2024globenewswire.com

SAN DIEGO, June 12, 2024 (GLOBE NEWSWIRE) -- Johnson Fistel, LLP (www.johnsonfistel.com), a shareholder rights law firm, announces its continuing investigation of whether certain directors and officers of Charles River Laboratories International, Inc. (NYSE: CRL) breached their fiduciary duties to...